Financials Luye Pharma Group Ltd.

Equities

Market Closed - Hong Kong S.E. Other stock markets 09:08:15 17/09/2024 BST			5-day change	1st Jan Change
2.960 ^HKD	+0.34%		0.00%	-20.64%

08-30	Citi Upgrades Luye Pharma to Buy From Sell; Price Target is HK$4	MT
08-28	Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	6,358	5,540	5,200	5,982	6,143	6,682	7,538	8,623
Change	-	-12.87%	-6.13%	15.03%	2.7%	8.77%	12.81%	14.4%
EBITDA ¹	2,553	1,877	906.9	1,813	2,077	1,953	2,086	2,395
Change	-	-26.47%	-51.69%	99.89%	14.6%	-5.98%	6.82%	14.78%
EBIT ¹	1,729	961.2	-6.49	747.6	872.9	1,360	1,451	1,716
Change	-	-44.42%	-	-	16.77%	55.77%	6.71%	18.26%
Interest Paid	-274.6	-424	-399.5	-471.8	-	-	-	-
Earnings before Tax (EBT) ¹	1,772	942.2	-74.56	669.8	700.1	1,008	1,162	1,449
Change	-	-46.82%	-	-	4.53%	43.94%	15.35%	24.67%
Net income ¹	1,469	706.6	-134.4	604.8	532.6	784.7	1,016	1,257
Change	-	-51.89%	-	-	-11.94%	47.33%	29.45%	23.78%
Announcement Date	26/03/20	31/03/21	29/03/22	29/03/23	27/03/24	-	-	-

¹CNY in Million

Estimates

Fiscal Period: December	2019 S2	2020 S1	2020 S2	2021 S1	2021 S2	2022 S1	2022 S2	2023 S1	2023 S2	2024 S2	2025 S1	2025 S2
Net sales ¹	3,227	2,962	2,577	2,952	2,249	2,851	3,131	2,904	3,239	3,433	3,191	3,879
Change	-	-8.2%	-12.99%	14.52%	-23.82%	26.78%	9.82%	-7.24%	11.53%	5.99%	-7.04%	21.55%
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-
EBIT ¹	-	-	-	-	521.8	589.5	300.6	-	-294.8	605.2	491.7	637.7
Change	-	-	-	-	-	12.98%	-49.01%	-100%	-	-	-18.75%	29.68%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT)	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-
Net income	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-
Announcement Date	26/03/20	27/08/20	31/03/21	29/08/21	29/03/22	29/08/22	29/03/23	29/08/23	27/03/24	-	-	-

¹CNY in Million

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	2,878	6,009	6,665	4,072	2,975	2,201	2,097	1,332
Change	-	108.79%	10.92%	-38.9%	-26.94%	-26.03%	-4.73%	-36.48%
Announcement Date	26/03/20	31/03/21	29/03/22	29/03/23	27/03/24	-	-	-

¹CNY in Million

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023
CAPEX ¹	728.2	970.4	692.8	556.2	655.7	632.7
Change	-	33.26%	-28.6%	-19.72%	17.89%	-3.51%
Free Cash Flow (FCF) ¹	-828.6	-3,394	399.7	-778.5	-43	629.1
Change	-	309.56%	-111.78%	-294.77%	-94.48%	-1,563.08%
Announcement Date	29/04/19	27/04/20	29/04/21	28/04/22	27/04/23	29/04/24

¹CNY in Million

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	40.16%	33.88%	17.44%	30.31%	33.82%	29.23%	27.68%	27.77%
EBIT Margin (%)	27.2%	17.35%	-0.12%	12.5%	14.21%	20.35%	19.25%	19.9%
EBT Margin (%)	27.87%	17.01%	-1.43%	11.2%	11.4%	15.08%	15.42%	16.8%
Net margin (%)	23.1%	12.76%	-2.58%	10.11%	8.67%	11.74%	13.48%	14.58%
FCF margin (%)	12.18%	6.15%	-7.19%	8.2%	-	-	-	-
FCF / Net Income (%)	52.74%	48.21%	278.16%	81.09%	-	-	-	-
Profitability
ROA	7.97%	4.56%	2.03%	-	-	-	-	-
ROE	17.24%	10.87%	-1.64%	6.48%	4.69%	5.9%	6.84%	7.91%
Financial Health
Leverage (Debt/EBITDA)	1.13x	3.2x	7.35x	2.25x	1.43x	1.13x	1.01x	0.56x
Debt / Free cash flow	3.72x	17.64x	-17.83x	8.3x	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	15.26%	12.51%	10.7%	19.45%	-	-	-	-
CAPEX / EBITDA (%)	38.01%	36.91%	61.33%	64.17%	-	-	-	-
CAPEX / FCF (%)	125.29%	203.39%	-148.78%	237.21%	-	-	-	-
Items per share
Cash flow per share ¹	0.5447	0.3242	0.0529	0.4751	-	-	-	-
Change	-	-40.48%	-83.68%	798.13%	-	-	-	-
Dividend per Share ¹	0.113	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	2.879	2.476	2.464	2.923	3.361	3.72	3.97	4.26
Change	-	-14.02%	-0.49%	18.65%	14.98%	10.68%	6.72%	7.3%
EPS ¹	0.4584	0.2212	-0.039	0.1738	0.1429	0.212	0.2461	0.3037
Change	-	-51.75%	-117.63%	-545.64%	-17.78%	48.38%	16.05%	23.43%
Nbr of stocks (in thousands)	3,268,965	3,248,965	3,541,372	3,549,671	3,761,671	3,761,671	3,761,671	3,761,671
Announcement Date	26/03/20	31/03/21	29/03/22	29/03/23	27/03/24	-	-	-